Home » Stocks » DARE

Dare Bioscience, Inc. (DARE)

Stock Price: $1.44 USD -0.10 (-6.49%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.46 +0.02 (1.39%) Jan 15, 6:06 PM
Market Cap 62.39M
Revenue (ttm) n/a
Net Income (ttm) -22.83M
Shares Out 31.59M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.44
Previous Close $1.54
Change ($) -0.10
Change (%) -6.49%
Day's Open 1.53
Day's Range 1.44 - 1.59
Day's Volume 1,027,349
52-Week Range 0.79 - 1.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 4 weeks ago

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, d...

Other stocks mentioned: MDNAF, SNOA
Seeking Alpha - 2 months ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Dare Bioscience (NASDAQ:DARE) moved higher by 0.9% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 20.00% year over year t...

GlobeNewsWire - 2 months ago

Conference Call Today at 4:30 p.m. Eastern Time Conference Call Today at 4:30 p.m. Eastern Time

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast a...

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Exe...

GlobeNewsWire - 3 months ago

Contraceptive Program Supported by approximately $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation to Date Contraceptive Program Supported by approximately $20.5 Million ...

Seeking Alpha - 3 months ago

Dare Bioscience: Preparing For The Upcoming Phase 3 Results

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and...

GlobeNewsWire - 4 months ago

Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff Agreement Intended to Facilita...

GlobeNewsWire - 4 months ago

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from t...

Seeking Alpha - 5 months ago

Daré Bioscience, Inc.'s (DARE) CEO Sabrina Martucci Johnson on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Ex...

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...

GlobeNewsWire - 5 months ago

More than 45 million women in the U.S. are approaching or in menopause More than 45 million women in the U.S. are approaching or in menopause

GlobeNewsWire - 6 months ago

Includes positive clinical findings from a postcoital test (PCT) human clinical study of Ovaprene®, an investigational hormone-free, monthly contraceptive

GlobeNewsWire - 6 months ago

Topline data readout anticipated by the end of 2020 Topline data readout anticipated by the end of 2020

GlobeNewsWire - 7 months ago

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from th...

Seeking Alpha - 8 months ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Conference Call Today at 4:30 p.m. Eastern Time

GlobeNewsWire - 8 months ago

SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a gran...

Seeking Alpha - 9 months ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is high...

GlobeNewsWire - 10 months ago

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previ...

GlobeNewsWire - 11 months ago

SAN DIEGO, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Coun...

24/7 Wall Street - 11 months ago

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

Other stocks mentioned: ADAP, AQST, BNTX, NKTR, NTGN
Seeking Alpha - 1 year ago

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Other stocks mentioned: ATNX, BSX, CFMS
GlobeNewsWire - 1 year ago

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit (Day 7-14) after a single administration in an investigator-initiated proof of concept study DAR...

GlobeNewsWire - 1 year ago

Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD

GlobeNewsWire - 1 year ago

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from th...

Seeking Alpha - 1 year ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from th...

GlobeNewsWire - 1 year ago

Sildenafil Cream, 3.6% produced statistically significant and clinically meaningful responses compared to placebo cream, further validating the potential for Sildenafil Cream, 3.6% to be an on...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executi...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Rep...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Offic...

Seeking Alpha - 1 year ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Daré Bioscience Inc. (DARE) CEO Sabrina Johnson on Q4 2018 Results - Earnings Call Transcript

Market Watch - 1 year ago

Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday.

Benzinga - 1 year ago

Dare Bioscience Inc, a nanocap biotech company focused on developing therapies for women's health, is enjoying a moment in the spotlight thanks to positive results for its vaginally administer...

About DARE

Daré Bioscience, a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Silden... [Read more...]

Industry
Biotechnology
CEO
Sabrina Martucci Johnson
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
DARE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 5.20, which is an increase of 261.11% from the latest price.

Price Target
$5.20
(261.11% upside)
Analyst Consensus: Buy